Colorectal cancer (CRC) accounts for about 8% of all new cancer cases diagnosed in the US. We used whole exome sequence data from triplet samples (colon carcinoma, colon adenoma, and normal tissue) from 18 individuals to assess gene mutation rates. Of the 2 204 genes that were mutated, APC, TTN, TP53, KRAS, OBSCN, SOX9, PCDH17, SIGLEC10, MYH6, and BRD9 were consistent with genes being an early driver of carcinogenesis, in that they were mutated in multiple adenomas and multiple carcinomas. Fifty-two genes were mutated in 12.5% of microsatellite stable (MSS) carcinomas but not in any of the adenomas, in line with the profile of a late driver event involved in tumor progression. Thirty-eight genes were sequenced in a larger independent set of 148 carcinoma/normal tissue pairs to obtain more precise mutation frequencies. Eight of the genes, APC, TP53, ATM, CSMD3, LRP1B, RYR2, BIRC6, and MUC17, contained mutations in >20% of the carcinomas. Interestingly, mutations in four genes in addition to APC that are associated with dysregulation of Wnt signaling, were all classified as early driver events. Most of the genes that are commonly associated with colon cancer, including APC, TP53, and KRAS, were all classified as being early driver genes being mutated in both adenomas and carcinomas. Classifying genes as potential early and late driver events points to candidate genes that may help dissect pathways involved in both tumor initiation and progression. 2-5
| I N TR ODU C TI ON
Colorectal cancer (CRC) is one of the most common cancers, accounting for about 8% of all new cancer cases diagnosed 1 in the US. The rate of new cases has been declining steadily over the past two decades 1 possibly due to increased screening and early detection and removal of precancerous lesions, adenomas or polyps. [2] [3] [4] [5] Early mutations in colon adenomas can initiate tumor development. 6 Cancers usually develop from the accumulation of genetic alterations that allow for tumor progression. Mutations at both the initiation and progression stages of the carcinoma can be considered as driver events by providing a growth advantage to the cells that harbor them. However, other acquired mutations may be passengers, in that they occur coincidentally with the drivers that provide the growth advantage.
Some of the most common genomic changes in CRC include mutations in the APC, TP53, and KRAS genes, DNA hypermethylation leading to the CIMP (CpG Island Methylator Phenotype), and mismatch repair deficiency that leads to genetic hypermutability that can be detected by Microsatellite Instability (MSI). NextGen sequencing (NGS) approaches have allowed higher resolution analysis of tumor samples in the search for additional genes important in the carcinogenic process.
In this study, we focused on samples from 18 progression. Genes mutated in adenomas but not the carcinomas could represent either random mutation events not important to cancer initiation, or rare events not seen in the carcinomas due to the relatively small number of samples evaluated. We analyzed each gene for the number and type of mutations present in the adenomas and carcinomas and how they relate specifically to microsatellite stable (MSS) and MSI tumors. Thirty-eight genes were further evaluated in 148 individuals to more precisely estimate their frequencies in the population. This information allowed us to classify genes into likely early and late driver events and to assess differences among the different tumor phenotypes.
| M A TE RI A L A ND M E TH ODS

| Study samples
Study samples come from a subset of participants in a larger epidemiologic study of colon cancer from Kaiser Permanente of Northern California (KPNC) and an eight-county area in Utah. 7 All participants analyzed in the study had previous data for TP53 mutations, 8 
| Calculations
The sequence coverage was calculated by multiplying the number of aligned reads to the capture target by 125 bp per read and dividing by 7.1x10 7 bp (71MB capture target) for each sample. The mean was then calculated for all the samples.
For adenomas and carcinomas, nonsynonymous coding mutation rates were calculated by: (total number mutations in the samples subset x 10 6 bases/MB)/(33,018,000 bases (total capture length of coding sequence in bases). Mean mutation rates were calculated for adenomas, MSS carcinomas, and MSI carcinomas.
Calculations of fold differences for mutations types between MSI
and MSS samples were calculated as a ratio of the mean number of a specific type of mutation per MSS carcinoma to that for the MSI carcinomas. This calculation was performed for both nonsynonymous and INDEL/frameshift mutations.
| APC mutation confirmation
All PCR amplifications were performed as previously described 17 for APC amplicons. Briefly, 12 mL reactions were amplified in 96-well tray format in GeneAmp 9700 PCR machines (Applied Biosystems, Foster City, CA) using AmpliTaq Gold DNA polymerase. In general, the thermocycler protocol used 10 min at 958C initial denaturation, followed by 30 cycles of 10 second denaturation at 958C, 10 second annealing at primer specific temperatures, and a 20 second extension at 728C.
Nested PCR conditions utilized 2 mL of a 25-fold dilution of the primary PCR product with the addition of internal primers. All DNA used for subsequent APC confirmation by PCR/Sanger sequencing confirmation used the same DNA that was used in the Exome capture sequence that identified the mutations. PCR products were treated with ExoSAP and sequenced using an ABI 3730 capillary sequencer (Applied Biosystems, Foster City, CA). Sequence data were analyzed using Sequencher v.5.3 (Gene Codes Corporation, Ann Arbor, MI).
| R E SU LTS
| Whole exome sequencing (WES)
WES achieved a mean coverage of 244X with a range of 73-390X.
The number of mutations identified in adenomas ranged from 38 to 585; for carcinoma samples the range of mutations was 31 to 1464 (Table 2) . This corresponded to a mean adenoma mutation rate of 4.59 mutations/MB, a mean MSS carcinoma mutation rate of 2.79 mutations/MB, and a mean MSI carcinoma mutation rate of 35.17/MB. The large differences in mutation rates between MSI and MSS tumors led to the analysis of tumors in these classifications separately.
| Early driver events: Analysis of adenomas
In the 17 adenomas analyzed, 2204 genes contained non-synonymous mutations (Supporting Information Table 2 ). Two hundred-thirty-nine genes were mutated in two or more (11.76%) of the adenomas and thirty-two genes were mutated in three or more (17.65%) of the adenomas ( were SOX9 with three frameshift mutations present in three carcinomas, CTNNB1 with two nonsense mutations, TGIF1 with two frameshift mutations, and BCL9L with one frameshift and one nonsense mutation.
Most mutations in other genes were skewed towards missense mutations. Eighty-four of the genes were mutated in two or more of the MSS carcinomas (>12.50%) but mutated in one or less (5.88%) of the adenomas; 52 of the mutated genes in MSS samples were not mutated The number and frequency of mutations in these genes that were seen in adenomas (AD) is listed. The mutation counts are subdivided into mutation types. The mutation count and mutation frequency seen in MSS carcinomas (CA) for these genes are also listed. The specific mutations and their codon effects are listed in Supporting Information Table 2. in any of the adenomas, suggesting a mutation pattern consistent with their being late drivers in the carcinogenic process.
Two carcinomas, classified as MSI-high, 18 were found to be hypermutated with 1 464 and 863 mutations each ( Table 2 ). The mean number of base substitution mutations was 785.5, 9.7-fold higher than the mean in the MSS carcinomas, and the mean number of INDEL/frameshifts mutations of 378 was 33.6 fold higher than the MSS carcinomas.
Of the 2 031 genes that were mutated in the two MSI-high carcinomas (Supporting Information Table 4) , 121 of the genes were mutated in both samples. Of these, 22 genes contained the same mutation in the two MSI tumors, and 18 of the 22 genes (ERRFI1, PHF2, RGL2, RNF43, ACVR2A, ARFGAP3, ARSJ, BRD3, C7orf49, CBX5, DDX27, EFCAB5, GRIN2A, MSH3, PROM1, RBM23, RPL22, and ZNRF3) shared the same location of the frameshift mutation at short mononucleotide repeats (Table 5 ). The two MSI cancers also shared MAP4K1 (P808A), NEK4
(S385C), BRAF (V600E), and KRT3 (G579S) missense mutations.
| Confirmation of NGS data
We attempted to confirm 43 of the mutations that we identified within the APC gene in adenomas and carcinomas by performing Sanger sequencing of PCR products. We confirmed 37 (86%) of the mutations found in the WES analysis. Thus, the majority of the mutations identified were validated by the use of an alternative sequencing method.
Five KRAS mutations had been previously identified in our carcinoma samples 9 and we validated all five of these mutations using the NGS of our exome captured DNA. We also identified two additional samples with KRAS mutations that were previously undetected. Both of these mutations were within the codon 12 and 13 hotspot previously scanned by Sanger methods. Seven samples had TP53 mutations, with three of the seven mutated samples previously identified from our hotspot exon 5-8 Sanger sequencing screen. 8 Of the four newly identified TP53 mutations, two were within the hotspot exons previously assessed by Sanger methods and the other two resided in exons 3 and 4 which were not previously scanned. Furthermore, two TP53 mutations previously identified in exon 5 were not identified in our WES sequence.
| Validation of mutation frequency
We chose to replicate mutation analysis to better ascertain mutation frequencies by performing exome capture sequencing on a targeted set of genes. Thirty-eight genes were sequenced in an additional 148 carcinoma/normal DNA pairs and evaluated for codon effecting mutations.
The 148 carcinomas had previously been characterized for tumor molecular phenotype (TP53 mutation containing, KRAS mutation containing, MSI status, CIMP status, or "None") allowing analysis within specific phenotypes as well as for MSS and MSI. [8] [9] [10] [11] Targeted exome capture sequencing achieved a mean depth of coverage of 1214X with a range of 489-2038X. The distribution of frequency of mutant genes in MSS and MSI carcinomas are shown in Table 6 (the frequencies of mutations for tumor phenotypes TP53, KRAS, CIMP, and for none previously identified are included in Supporting Information Table 5 ). Specific mutations for each gene are presented in Supporting Information 
| D ISC USSION
Sequence analysis of all coding genes in colon carcinomas, adenomatous polyps, and paired normal DNAs is helpful in understanding their potential roles in carcinogenesis. Analysis of both adenomas and Cancer Genome Atlas Network (TCGA). 19 In addition, they saw less frequently mutated FBXW7 (11%), SMAD4 (10%), TCF7L2 (9%) and NRAS (9%). In our sample set we also confirm that these genes were mutated in one of the carcinomas analyzed each (6.25%) (Supporting Information 20 Thus, it is logical that a truncated SOX9 could lead to an accumulation of b-catenin. CTNNB1 mutations have been described in colon cancer that activate b-catenin and make it insensitive to wt APC. 21 Inhibition by wt APC is mediated through phosphorylation of serine/threonine residues. Mutation of these residues leads to activation of b-catenin independent of mutant APC. We observed three mutations in CTNNB1. One was identified in an adenoma where codon 45, a serine, was deleted (S45Del). This deletion of a phosphorylation site was reported by Morin et al. 21 as an activating mutation.
The other two mutations were nonsense mutations identified in carcinomas (R95X and Q773X). One of these carcinomas also contained a single APC mutation while the other harbored two APC mutations. As these two carcinomas also likely contained a wt copy of CTNNB1 it remains possible that the APC mutations could still be driving the canonical Wnt-signaling pathway. While over 40 truncating mutations in CTNNB1 have been reported in the COSMIC database, 22 it is unlikely that they all work through the transcription factor activity associated with canonical Wnt signaling. Perhaps the truncating mutations contribute to tumor formation through b-catenin's alternate role in adheren junctions by disrupting cellular contact inhibition. 23 To evaluate whether genes are likely early drivers in the carcinogenesis process of colon carcinomas, we determined which genes were mutated in both adenomas and carcinomas. Many of the known commonly mutated genes in colon cancer were among these early events, including APC, KRAS, and TP53. It is worth noting that, in addition to APC, three other members of the Wnt-signaling pathway SOX9, AMER1, and PRICKLE2 are among these potential early driver genes.
In addition, we identified 52 genes that were only seen mutated in two or more MSS carcinoma but not in any of the adenomas. These could represent genes that drive events later in the carcinogenic process. It is worth noting that these 52 genes do not include any of the commonly known mutated colon cancer genes. Three of the genes from the set of late candidates were chosen for additional sequencing in the 148 additional samples: BIRC6, CCDC105, and RBMXL3. BIRC6
and RBMXL3 both confirmed their frequent mutation rates in MSS carcinomas (18.75% vs. 12.5% in the first cohort and 14.06% vs. 12.5%, respectively). No adenomas were included in the replication set, precluding confirmation of the mutations as strictly late events. Notably, all three of these genes were mutated frequently in the additional replication set of MSI carcinomas [BIRC6 (30%), CCDC105 (15%), and RBMXL3 (25%)]. All of these mutations were unique and none represented apparent slippage events at coding mononucleotide repeats. The two previously identified MSI carcinomas were hypermutated with an excess of both missense/nonsense mutations and INDEL/frameshift mutations as compared to MSS tumors studied (9.7 fold and 33.6 fold, respectively). The high mutation frequency is consistent with observations of other groups. 19 One hundred and twenty-one genes were found to be mutated in both of the MSI tumors in this study.
Twenty-one of these genes likely harbor a hotspot for mutation as the same location was mutated in both samples. Only three of these genes were highlighted by the TCGA as frequent targets for mutation, ACVR2A, MSH3, and BRAF (V600E). Of the 21 genes with the same location mutated, all but four were frameshift mutations occurring at mononucleotide repeats as others have seen in mismatch repair deficient MSI tumors. 24 The four genes with recurrent missense mutations were NEK4, KRT3, BRAF, and MAP4K1. Only the BRAF (V600E), MSH3
(K381fs), and RNF43 (G659fs) have been previously reported to be a hotspot mutation in many cancers. [25] [26] [27] [28] [29] We employed a targeted exome capture and sequencing strategy to further evaluate 38 genes on an additional 148 colon carcinoma/ normal paired samples. Six genes were chosen for their mutation frequencies in MSS carcinomas. All were seen to be mutated in both MSS and MSI carcinomas, consistent with the TCGA data. Both APC and TP53 exhibited lower mutation frequencies in MSI tumors than in MSS carcinomas. In this larger sample set, PXDN, SOX9, and TMEM132C all showed a MSS mutation rate below 10%; however, PXDN had an 11.76% mutation rate in KRAS mutation containing carcinomas and SOX9 had a 21.05% mutation rate in carcinomas exhibiting the "none previously identified" phenotype (Supporting Information Table 5 ). Perhaps SOX9 plays a more important role in carcinomas lacking the commonly defined tumor molecular phenotypes. Thirteen genes were selected from our results classifying early driver mutations. Only BRD9 failed to show an appreciable mutation frequency compared to our whole exome results (1.56% vs. 12.5%, respectively). All the other potential early driver genes appear to have appreciable mutation frequencies across both MSS and MSI tumor molecular phenotypes (5%). Three of the genes defined as late drivers also were sequenced.
Only CCDC105 failed to show an appreciable mutation rate in the MSS mutations were p.P808A, and one of one EFCAB5 mutation was p.
R809fs. We evaluated seven genes that were only mutated in adenomas and not in carcinomas (Table 3 and Supporting Information Table   2 ). In the validation data set, they were all found to be mutated in both MSS and MSI samples at low (10%) frequency with the exception of DIAPH1 and MUC17 that were more frequently mutated (14.8% in MSS and 10% in MSI tumors for DIAPH1 and 21.09% in MSS and 25%
in MSI for MUC17). These genes may represent additional early event genes in carcinogenesis.
One of the most frequently mutated genes overall in the replication set was RYR2 which was part of both the early MSS mutated genes and MSI mutated genes. The mean number of codon effecting mutations in adenomas was 151.8, exceeding the mean identified in MSS carcinomas at 92.3 ( Table   2 ). This difference might be due to the few adenomas exhibiting a high number of mutations, perhaps they are beginning to exhibit a hypermutable phenotype. While testing for MSI was not performed on the adenomas, the adenoma from sample ID 3 which contained 585 nonsynonymous mutations contained both a POLE (L1561fs) and a POLD3 mutation (Q104fs) consistent with a hypermutable phenotype. 32 No known cause for hypermutability was identified in the adenoma from sample ID 6 which contained 434 non-synonymous mutations. Removing the two adenomas with a high mutation count (ID 3 and ID 6) from the means calculation would lower the resulting value to 104.1. This would suggest that adenomas and carcinomas contain a very similar number of mutations. Among the commonly mutated colon cancer genes, APC, KRAS, and TP53, all revealed high mutation rates in adenomas and carcinomas, suggesting they may be necessary for initiation of adenomas, but are unlikely to be the gene that drives transition to become a carcinoma. Further examination of potential late driver genes may shed light on pathways involved in tumor progression.
It is interesting that six genes from the Wnt-signaling pathway were identified as being mutated in our original carcinoma screen (APC, CTNNB1, SOX9, AMER1, PRICKLE2, and RNF43), all except CTNNB1 can be defined as early driver events based on being mutated in both carcinomas and adenomas. CTNNB1 could not be categorized as an early event gene as the adenoma mutation was considered an activating mutation and the MSS carcinomas contained inactivating mutations.
Disruption within the Wnt-signaling pathway, would appear to be a necessary event early in tumorigenesis but not sufficient to lead to carcinoma formation. Other specific mutations would be required for that transition to occur.
RNF43 a negative regulator of Wnt signaling was mutated in one MSS carcinoma, one adenoma, and two MSI carcinomas in our WES sample set. The adenoma and MSS mutations (D595V and L12fs, respectively) were not mutated at a coding mononucleotide repeat, while the two mutations identified in the MSI samples involved frameshifts in coding mononucleotide repeats (G659fs and R117fs Other studies of colon cancer mutation such as the TCGA have evaluated large numbers of samples by WES. A strength of this study is that we were also able to compare mutation rates for genes seen in adenomas and carcinomas from the same individual to better ascertain whether genes were likely early drivers of carcinogenesis versus those that occur later in the carcinogenic process. Although our whole exome study included only 18 carcinomas, most of the genes were found to be mutated frequently in the larger validation set of 148 carcinomas.
Our study both confirms the findings of other WES studies on colon carcinomas, but also puts forth additional candidate genes that are frequently mutated in colon carcinogenesis and at various stages of the process. We encourage other to further investigate the role that these genes play in colon cancer.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article. 
